COMMUNIQUÉS West-GlobeNewswire

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
06/07/2026
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to [...]
Nephros Announces Inclusion in the Russell Microcap® Index
06/07/2026
SOUTH ORANGE, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that the [...]
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
06/07/2026
Leading Vascular Specialist and Penumbra Chief Medical Officer Joins GuideAI to Help Advance Its Recently FDA-Cleared VAOT Triage Software BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (Cboe CA: GDAI [...]
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
06/07/2026
U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food and Drug [...]
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
06/07/2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
06/07/2026
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review [...]
NovMetaPharma and the FSHD Canada Foundation Establish Collaboration to Advance Cyclo-Z, a First-in-Class Oral Muscle-Preserving Therapy, into Facioscapulohumeral Muscular Dystrophy
06/07/2026
Disease-foundation-funded program extends NovMetaPharma’s muscle-preservation platform into a serious neuromuscular disease with no approved disease-modifying treatment; collaboration provides non-dilutive capital to [...]
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
06/07/2026
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of [...]
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
06/07/2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
La recommandation du CMUH fait passer le TECVAYLI®▼ (teclistamab) de Johnson & Johnson, associé au daratumumab, au rang de traitement conventionnel potentiel pour le myélome multiple récidivant ou réfractaire
06/07/2026
Recommandation étayée par des données inédites issues d’une étude de Phase 3, démontrant que TECVAYLI ® , en association avec le daratumumab, a permis d’obtenir des améliorations statistiquement significatives en termes [...]
Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential
06/07/2026
Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation Highly Qualified, Independent and Accountable Board Has Taken Decisive [...]
ThreeSixty Journalism Kicks Off Multimedia Storytelling Institute Summer Program for Local High School Students
06/07/2026
Summer Program Gives High School Students Hands-On Reporting Experience Exploring Mental Health and Wellness Across Minnesota ST. PAUL, Minn., July 06, 2026 (GLOBE NEWSWIRE) -- This July, ThreeSixty Journalism will kick [...]
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
06/07/2026
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food [...]
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
06/07/2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as [...]
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
06/07/2026
Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG [...]
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
06/07/2026
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology [...]
Novo Nordisk A/S - share repurchase programme
06/07/2026
Bagsværd, Denmark, 6 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
06/07/2026
Led by the venture arm of a strategic partner, proceeds will support inventory build and commercialization of proprietary polyclonal stem cells engineered with safety and universality features to support diverse [...]
Integrated Development Helps Targeted Protein Degraders Reach the Clinic
06/07/2026
Design of targeted protein degraders is more than target degradation. Linker architecture, molecular flexibility, solubility, permeability, synthesis, purification, and formulation can all influence whether a candidate [...]

Pages